酪氨酸和苏氨酸蛋白激酶在结直肠癌发生发展中的表达及其与预后的关系
研究用AOM-DSS诱导C57BL/6小鼠结肠癌模型及24对结直肠癌标本,检测TTK mRNA和蛋白表达,并分析GEO公共芯片数据。结果显示TTK表达随结肠癌发生发展逐渐升高,在癌组织中高于癌旁组织,且高表达与不良预后相关。
要点
- 小鼠结肠癌模型中TTK mRNA随炎症恢复期、轻度不典型增生、腺瘤、腺癌进展逐渐升高。
- 24例结直肠癌患者肿瘤组织TTK mRNA为0.71±0.10,高于配对癌旁组织的0.18±0.04(P<0.001)。
- GSE17536数据分析显示TTK高表达与结直肠癌患者不良预后相关。
核心结论
- 小鼠模型和人类结直肠癌标本中TTK表达升高与结肠癌发生相关,TTK是结直肠癌的不良预后因素。
研究设计与样本
- 联合应用氧化偶氮甲烷(AOM)和葡聚糖硫酸钠(DSS)诱导C57BL/6小鼠结肠炎相关结肠癌,获得炎症恢复期(AD1)、轻度不典型增生(AD2)、腺瘤(AD3)、腺癌(AD4)4个阶段模型及无处理对照组。
- 应用实时荧光定量PCR和免疫组化法检测不同阶段小鼠结肠及24对结直肠癌与配对癌旁组织中TTK mRNA和蛋白表达。
- 从美国国家生物技术信息中心(NCBI)基因表达公共数据库获取结直肠癌全基因组芯片数据,分析TTK表达与结直肠癌患者预后的关系。
主要发现
- AOM-DSS结肠癌小鼠模型全基因组表达芯片显示,TTK mRNA表达水平随结肠癌发生发展逐渐升高。
- 实时荧光定量PCR检测对照组、AD1、AD2、AD3和AD4组小鼠结肠组织TTK mRNA水平分别为1.05±0.42、1.10±0.03、1.38±0.15、1.33±0.17和2.12±0.22。
- AD2、AD3和AD4组小鼠结肠组织TTK mRNA水平均明显高于对照组(均P<0.05)。
- 免疫组化检测小鼠结肠组织TTK蛋白表达变化与TTK mRNA检测结果一致。
- 24例结直肠癌患者肿瘤组织TTK mRNA水平为0.71±0.10,明显高于配对癌旁组织的0.18±0.04(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the expression of TTK (tyrosine and threonine protein kinase) in the process of colorectal cancer (CRC) development and its relationship to prognosis in CRC patients. Methods: Colitis-associated colon cancer model was induced by azoxymethane (AOM) and dextran sulfate sodium (DSS) in C57BL/6 mice. Mice at four different stages of colon cancer development were obtained, named AD1 (inflammation of the recovery), AD2 (mild dysplasia), AD3 (adenoma) and AD4 (adenocarcinoma), as well as negative control (no treatment). The expression of TTK was measured by real time fluorescent quantitative PCR (qPCR) and immunohistochemical staining in mouse colon tissues and 24 pairs of CRC specimens. The relationship between TTK and prognosis was analyzed in a set of CRC genome-wide gene expression microarray data that was obtained from Gene Expression Omnibus (GEO) of National Center for Biotechnology Information (NCBI). Results: The genome-wide microarray data from mouse AOM-DSS model indicated that the expression of TTK mRNA was gradually elevated during the development of colon cancer. The subsequent qPCR results showed that TTK mRNA levels in negative control, AD1, AD2, AD3 and AD4 groups were 1.05±0.42, 1.10±0.03, 1.38±0.15, 1.33±0.17 and 2.12±0.22, respectively. And TTK expression in AD2, AD3 and AD4 groups were significantly higher than that in negative control (P<0.05). The protein expression of TTK showed by immunohistochemical staining had similar tendency as the results of TTK mRNA. Besides that, the TTK mRNA levels in tumor tissues (0.71±0.10) from 24 CRC patients were significantly higher than those in paired adjacent normal tissues (0.18±0.04; P<0.001). The positive expression rate of TTK protein in 5 pairs of CRC clinical samples was 80.0%, and it was significantly higher than that in adjacent normal tissues (30.8%, P=0.014). Furthermore, according to a public transcriptomic data (GSE17536), the high levels of TTK were associated with poor prognosis in CRC patients. Conclusions: Elevated expression of TTK is related to colonic carcinogenesis in both of mouse model and human CRC samples. TTK is a poor prognostic factor in CRC. 目的: 探讨酪氨酸和苏氨酸蛋白激酶(TTK)在结直肠癌发生发展中的表达变化及与结直肠癌患者预后的关系。 方法: 联合应用氧化偶氮甲烷(AOM)和葡聚糖硫酸钠(DSS)诱导C57BL/6小鼠发生结肠炎相关的结肠癌,得到结肠癌发生发展的4个不同阶段的小鼠模型(分别为炎症恢复期、轻度不典型增生、腺瘤、腺癌),同时设立无任何处理的对照组。应用实时荧光定量PCR和免疫组化法检测不同阶段小鼠结肠和24对结直肠癌及其配对的癌旁组织中TTK mRNA和蛋白的表达水平。从美国国家生物技术信息中心(NCBI)基因表达公共数据库中获取结直肠癌全基因组芯片数据,分析TTK的表达与结直肠癌患者预后的关系。 结果: AOM-DSS结肠癌小鼠模型的结肠全基因组表达芯片显示,TTK mRNA的表达水平随着结肠癌的发生发展逐渐升高。实时荧光定量PCR检测结果显示,对照组、炎症恢复期、轻度不典型增生、腺瘤和腺癌小鼠结肠组织中TTK mRNA的表达水平分别为1.05±0.42、1.10±0.03、1.38±0.15、1.33±0.17和2.12±0.22,轻度不典型增生、腺瘤和腺癌小鼠结肠组织中TTK mRNA的表达水平均明显高于对照组(均P<0.05)。免疫组化检测对照组、炎症恢复期、轻度不典型增生、腺瘤和腺癌小鼠结肠组织中TTK蛋白的表达变化与TTK mRNA的检测结果一致。24例结直肠癌患者肿瘤组织中TTK mRNA的表达水平为0.71±0.10,明显高于配对的癌旁组织(0.18±0.04,P<0.001)。免疫组化检测5例结直肠癌患者肿瘤组织中TTK蛋白的阳性表达率为80.0%,明显高于配对的癌旁组织(30.8%,P=0.014)。全基因组芯片网络数据(GSE17536)分析显示,TTK的高表达与结直肠癌患者的不良预后有关。 结论: 在结肠癌的小鼠模型中,TTK的表达随着肿瘤的发生发展逐渐升高;在临床结直肠癌标本中,TTK的高表达与患者的不良预后相关。.
引用
- Zhang XL, Han WX, Ma YM, et al. [Expression of tyrosine and threonine protein kinase in carcinogenic process of colorectal cancer and its relationship with prognosis]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28316214. doi:10.3760/cma.j.issn.0253-3766.2017.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。